BC Cancer at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
BC Cancer brings 3 presentations to ASH 2026 in New Orleans. Its program centres on diffuse large B-cell lymphoma, from frontline treatment to how aggressive B-cell lymphomas are classified. It also looks at the clinical meaning of mutations in non-coding parts of the lymphoma genome.
| Organization | ASH 2026 Attendance |
|---|---|
BC Cancer Vancouver, Canada | |
Provincial cancer care and research agency of British Columbia, part of the Provincial Health Services Authority. | Talk New Dimensions in the Classification of Aggressive B-cell Lymphomas: What Are We Missing? Single-cell profiling, spatial gene mapping, and whole genome sequencing trace how aggressive B cell lymphomas develop from common precursor cells. Talk Clinical Relevance of Non-Coding Mutations Why non-coding mutations, often left by the machinery that diversifies antibodies, matter for the biology, subtypes and clinical behavior of B-cell lymphomas. Session Diffuse Large B-cell Lymphoma The fast-changing treatment of diffuse large B-cell lymphoma, from new first-line combinations to CAR-T cells, bispecific antibodies and other targeted drugs. Talk Frontline Therapy of Diffuse Large B-Cell Lymphoma Recent trials of new first-line combinations for diffuse large B-cell lymphoma, and how subtype, stage, risk, age and heart health guide the choice. |
Instantly find 20 buyers from BC Cancer
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction